Table 1.
Baseline characteristics and disease outcome between unvaccinated and completed mRNA vaccination COVID-19 B1.617.2 infected patients
| Unvaccinated n = 130 | Vaccinated n = 71 | p | |
|---|---|---|---|
| Median age (IQR), years | 39.5 (30–58) | 56 (39–64) | <0.001 |
| Male (%) | 67 (51.5) | 27 (38) | 0.067 |
| Median Charlson Comorbidity Index (IQR) | 0 (0–1) | 0 (0–0) | 0.125 |
| Diabetes mellitus (%) | 28 (21.5) | 5 (7.0) | 0.008 |
| Hypertension (%) | 28 (21.5) | 14 (19.7) | 0.762 |
| Hyperlipidaemia (%) | 32 (24.6) | 18 (25.4) | 0.908 |
| Median Ct value on diagnosis (IQR) | 18.8 (14.9–22.7) | 19.2 (15.2–22.2) | 0.929 |
| Asymptomatic | 12 (9.2) | 20 (28.2) | <0.001 |
| Symptom onset after diagnosis (%) | 11 (8.5) | 11 (15.5) | 0.030 |
| Median day of illness symptoms start (IQR) | 2 (2–3) | 3 (2–3) | 0.715 |
| Median Ct values for symptom onset after (IQR) | 21.87 (18.8–31.2) | 19.2 (16.6–21.5) | 0.279 |
| Median sum of symptoms reported (IQR) | 2 (1–3) | 1 (0–2) | <0.001 |
| Fever (%) | 96 (73.9) | 29 (40.9) | <0.001 |
| Cough (%) | 79 (60.8) | 27 (38) | 0.002 |
| Shortness of breath (%) | 17 (13.1) | 1 (1.4) | 0.004 |
| Runny nose (%) | 31 (23.8) | 27 (38) | 0.034 |
| Sore throat (%) | 43 (33.1) | 18 (25.4) | 0.255 |
| Diarrhoea (%) | 8 (6.2) | 0 | 0.052 |
| Median highest neutrophil (IQR) × 109/L | 4.50 (3.07–5.92) | 4.33 (3.52–5.43) | 0.117 |
| Median lowest lymphocyte (IQR) × 109/L | 0.95 (0.65–1.50) | 1.36 (1.02–1.87) | <0.001 |
| Median highest C-Reactive protein (IQR), mg/L | 24.7 (6.9–84.8) | 12.6 (6.5–22.5) | <0.001 |
| Median highest lactate dehydrogenase (IQR), U/L | 486 (365–672) | 373 (314–421) | 0.062 |
| Median highest alanine transferase (IQR), U/L | 35 (18–74) | 19 (13–34) | <0.001 |
| Disease outcome | |||
| Pneumonia (%) | 69 (53.1) | 9 (12.7) | <0.001 |
| Supplementary O2 required (%) | 27 (20.8) | 2 (2.8) | <0.001 |
| ICU admission required (%) | 7 (5.4) | 0 | 0.053 |
| Median days of ICU admission required (IQR) | 4 (3–9) | — | — |
| Intubation (%) | 2 (1.5) | 0 | 0.541 |
| Median days of Intubation (IQR) | 7 (3–11) | — | — |
| COVID-19 specific treatment (%) | 39 (30) | 5 (7) | <0.001 |
| Mortality | 2 (1.54) | 0 | 0.541 |